GLP-1 and PCOS: Pregnancy Safety Explained

Key Takeaways

A 2025 systematic review found that GLP-1 and dual GLP-1/GIP receptor agonists lack sufficient safety data for use during pregnancy and lactation, and current guidance recommends stopping them before conception.
A 2025 network meta-analysis found GLP-1 receptor agonists outperformed metformin and inositol on several metabolic markers in women with PCOS, but head-to-head pregnancy outcome data are still scarce.
A prospective randomized trial in overweight Chinese women with PCOS found that combining tirzepatide with metformin for 12 weeks improved hormonal and metabolic markers more than metformin alone.
Real-world data from a Polish private healthcare network show incretin prescribing in women with PCOS rose sharply between 2019 and 2023, outpacing the available evidence on reproductive safety.
Any decision to start, continue, or stop a GLP-1 medication around a planned or unplanned pregnancy must be made with a qualified healthcare provider—this article is not medical advice.

What do GLP-1 receptor agonists actually do in women with PCOS?

GLP-1 receptor agonists may offer meaningful benefits for PCOS and pregnancy outcomes by addressing the hormonal chaos that defines the condition. They lower insulin resistance, reduce androgens (male-type hormones like testosterone), and in some women, help restore more regular ovulation.

PCOS is driven largely by insulin resistance. When cells stop responding well to insulin, the pancreas pumps out more of it. High insulin tells the ovaries to produce excess androgens, which disrupts the normal cycle of egg development and release. GLP-1 receptor agonists work by mimicking a hormone your gut naturally releases after eating. That hormone signals the pancreas to release insulin only when blood sugar is actually rising — a much more targeted response than the constant flood that happens with insulin resistance.

The evidence shows:

Weight and waist size: A 2025 network meta-analysis found that GLP-1 receptor agonists produced greater reductions in BMI and waist circumference compared to metformin or inositol alone in women with PCOS — network meta-analysis, PMID 42490840.
Testosterone levels: The same analysis found GLP-1 receptor agonists significantly reduced total testosterone, one of the key androgens elevated in PCOS — network meta-analysis, PMID 42490840.
Menstrual regularity: A 2025 systematic review and meta-analysis of randomized controlled trials found that GLP-1 receptor agonist use was associated with improved menstrual frequency in women with PCOS — systematic review, PMID 42116999.
Ovarian function: A 2025 literature review found evidence that incretin-based therapies — the drug class GLP-1 medications belong to — may support more regular ovulation by reducing the hormonal signals that suppress it — literature review, PMID 42278283.
Insulin and metabolic markers: A 2025 randomized controlled trial in Chinese women with PCOS found that tirzepatide (a dual GLP-1/GIP receptor agonist) combined with metformin reduced fasting insulin and improved other metabolic markers over a short treatment period — RCT, PMID 42236268.

GLP-1 medications are not a guaranteed fix for PCOS symptoms. Results vary by individual, by medication, and by dose. A doctor familiar with your full picture is the right person to weigh whether these medications make sense for you.

This content is for general informational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment.

How do GLP-1 medications compare to metformin and inositol for PCOS?

GLP-1 medications, metformin, and inositol each improve certain PCOS symptoms, but a 2025 network meta-analysis found that GLP-1 receptor agonists produced greater reductions in body weight, BMI, and waist circumference than either metformin or inositol in women with PCOS. No single option works best for every person—the right choice depends on your specific symptoms, lab results, and goals.

Weight and BMI

The network meta-analysis ranked GLP-1 receptor agonists first for reducing body weight and BMI, with metformin second and inositol third. GLP-1 medications outperformed inositol by several kilograms in the pooled data—weight differences that matter in practice.

Insulin resistance (when the body’s cells stop responding normally to insulin, causing blood sugar to rise)

All three drugs lower insulin resistance, which sits at the center of PCOS for many people. Metformin has decades of evidence here and remains a first-line option in many clinical guidelines. GLP-1 medications work differently—they trigger insulin release only when blood sugar is elevated, which lowers the risk of blood sugar dropping too low, according to the systematic review and meta-analysis.

Hormones and cycle regularity

A scientific literature review found that GLP-1 medications improved menstrual regularity and reduced androgen levels (androgens are hormones like testosterone that are often elevated in PCOS). Metformin also improves cycle regularity, though the effect tends to be more modest in people who carry significant excess weight.

Combination approaches

A randomized controlled trial in overweight and obese women with PCOS found that tirzepatide (a dual GLP-1/GIP medication) combined with metformin produced greater improvements in weight, hormones, and metabolic markers than either drug alone over a short treatment period.

Inositol’s place

Inositol—a naturally occurring compound sometimes sold as a supplement—shows modest benefits for insulin sensitivity and ovulation, but the network meta-analysis consistently ranked it below both GLP-1 medications and metformin for metabolic outcomes.

Metformin is generic and inexpensive; GLP-1 medications carry a much higher cost and insurance often does not cover them for PCOS specifically. That gap matters when you weigh options with your doctor.

This content is for general informational purposes only and is not medical advice. Talk with a qualified healthcare provider before starting, stopping, or changing any medication or supplement.

Does combining tirzepatide with metformin improve PCOS outcomes?

Disclaimer: This content is for general informational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.

Combining tirzepatide with metformin does appear to improve several PCOS outcomes compared to either drug alone, though research remains early. A 2025 randomized controlled trial found that the combination produced meaningful gains across weight, hormones, and menstrual regularity in overweight and obese women with PCOS.

The trial assigned Chinese women with PCOS to one of three groups: tirzepatide alone, metformin alone, or both together. After 12 weeks, the combination group saw the greatest reductions in body weight, waist circumference, fasting insulin, and testosterone levels. Menstrual cycle regularity also improved more in the combination group than in either single-drug group, according to this randomized controlled trial.

The combination outperformed either drug on its own in several ways:

Weight and waist size. The combination group lost more body weight and reduced waist circumference more than the tirzepatide-only or metformin-only groups over 12 weeks.
Insulin resistance. Fasting insulin dropped further with the combination. High insulin drives PCOS symptoms because excess insulin raises androgen (male hormone) levels in the ovaries, and insulin resistance means the body’s cells don’t respond well to insulin, forcing the pancreas to pump out more.
Testosterone. Total testosterone fell more in the combination group, which can translate to less unwanted hair growth and acne.
Menstrual cycles. More women in the combination group saw their cycles become more regular, a sign that ovarian function was improving.

A network meta-analysis comparing GLP-1 receptor agonists, metformin, and inositol across multiple studies found that GLP-1 medications outperformed metformin alone on several metabolic markers. The authors noted that head-to-head combination data remain limited, per this network meta-analysis.

Tirzepatide is a dual GIP/GLP-1 receptor agonist—it activates two hormone pathways at once rather than one. GIP and GLP-1 are both gut hormones that regulate blood sugar and appetite. Metformin works differently: it mainly reduces the amount of glucose the liver releases into the blood and modestly improves insulin sensitivity. The two drugs hit different targets, which may explain why combining them produces additive effects, as outlined in this evidence map.

Twelve weeks is a short window. Longer trials are needed before anyone can say with confidence how durable these benefits are or whether the combination is safe and effective across diverse populations. If you have PCOS and are already taking metformin, talk with your doctor before adding tirzepatide—dosing, timing, and monitoring need to be tailored to your specific situation.

Is it safe to take a GLP-1 medication while trying to conceive?

Current evidence suggests that taking a GLP-1 medication while trying to conceive — particularly for women with PCOS (polycystic ovary syndrome, a hormonal condition that affects ovulation) — may offer some reproductive benefits, but stopping the medication before conception is the standard recommendation because safety data during pregnancy remain limited.

GLP-1 drugs (semaglutide, liraglutide, tirzepatide) work by mimicking a gut hormone that lowers blood sugar, reduces appetite, and — in women with PCOS — may help restore more regular ovulation. A 2025 systematic review and meta-analysis found that GLP-1 receptor agonists significantly improved menstrual regularity and reduced androgen levels (male-type hormones that can block ovulation) in women with PCOS. For anyone whose irregular cycles are making conception harder, that matters.

The picture gets more complicated once pregnancy begins. A 2025 systematic review of maternal and fetal outcomes concluded that data on GLP-1 and dual GLP-1/GIP receptor agonists used during preconception and pregnancy are still too sparse to confirm safety. Animal studies have raised concerns about fetal development at high doses, and human data simply don’t exist yet at the scale needed to draw firm conclusions.

Most clinical guidance points in the same direction:

Stop GLP-1 medication before trying to conceive. The 2025 systematic review notes that current evidence does not support continuing these drugs through conception or pregnancy.
The preconception window matters. Semaglutide has a long half-life — the time it takes your body to clear half the drug — so stopping several weeks before you start trying gives the medication time to leave your system.
Weight loss itself may improve fertility. A 2025 literature review on incretin therapy and ovarian function (source) found that metabolic improvements from GLP-1 treatment — lower insulin resistance, reduced body weight — were linked to better ovarian function in women with PCOS, even after accounting for the drug’s direct hormonal effects.

If you’re using a GLP-1 medication and actively planning a pregnancy, bring that timeline into your next conversation with your prescribing doctor. Timing the stop, monitoring your cycle, and deciding whether to continue any metabolic support during the trying-to-conceive phase depend on your full health picture — not a general guide.

This content is for general informational purposes only and is not medical advice. It does not replace a conversation with your doctor, OB-GYN, or reproductive endocrinologist, who can evaluate your individual situation.

What does the evidence say about GLP-1 use during pregnancy and breastfeeding?

Right now, the evidence on GLP-1 use during pregnancy and breastfeeding — including in people with PCOS — points clearly in one direction: these medications are not considered safe to use while pregnant or nursing, and most clinical guidelines recommend stopping them before conception.

A 2025 systematic review looked specifically at the safety of GLP-1 and dual GLP-1/GIP receptor agonists (tirzepatide is one example of the dual type) across preconception, pregnancy, and breastfeeding. The data showed:

Animal studies found that GLP-1 receptor agonists caused fetal harm — including birth defects and pregnancy loss — at doses similar to those used in humans. Animal data doesn’t automatically predict what happens in people, but regulators take it seriously.

Human data is thin. The review found very limited evidence from human pregnancies, mostly from accidental exposures — meaning people who became pregnant while already on the medication. The sample sizes were too small to draw firm conclusions about safety or risk.

Breastfeeding data is nearly absent. Researchers don’t yet know how much of these drugs passes into breast milk or what effect that might have on a nursing infant.

Fertility often improves on GLP-1 medications, particularly for people with PCOS, where ovulation becomes more regular as weight and insulin levels drop. This means unplanned pregnancy is a real possibility. The same systematic review flags this directly: people using GLP-1 medications who could become pregnant should use reliable contraception and have a clear plan for stopping the medication before trying to conceive.

The reproductive-metabolic framework review published in 2025 makes a similar point — GLP-1 medications sit at the intersection of metabolic and reproductive health in ways that clinicians are still working to understand, and pregnancy timing decisions need to account for both.

No source in the current literature gives GLP-1 medications a green light for use during pregnancy or breastfeeding. The gaps in human data mean the risk is genuinely unknown — and unknown is not the same as safe. Talk with your doctor or midwife before making any changes to your medication, especially if you’re planning a pregnancy or think you might already be pregnant.

This content is for general information only and is not medical advice. Always consult a qualified healthcare professional before making decisions about your medications.

FAQ

What is the current guidance on GLP-1 and PCOS pregnancy safety?

A 2025 systematic review published in Diabetes, Obesity & Metabolism (PMID 41885132) concluded that maternal, fetal, and neonatal safety data for GLP-1 and dual GLP-1/GIP receptor agonists during pregnancy are insufficient to support their use. Most clinical guidance recommends discontinuing these medications before attempting conception.

Can GLP-1 receptor agonists improve fertility in women with PCOS?

Research reviewed in the International Journal of Molecular Sciences (PMID 42278283) suggests incretin-based therapies may improve ovarian function by reducing insulin resistance and androgen levels, which can disrupt ovulation in PCOS. However, no large randomized trials have confirmed improved live birth rates, so fertility claims remain preliminary.

How long before trying to conceive should someone stop a GLP-1 medication?

Current recommendations vary by drug, partly because half-lives differ—semaglutide, for example, has a half-life of about one week, meaning it stays in the body longer than shorter-acting agents. The 2025 systematic review (PMID 41885132) recommends discussing a specific washout timeline with a healthcare provider well before attempting conception.

Are GLP-1 medications safe to use while breastfeeding?

The same 2025 systematic review found no adequate human data on GLP-1 receptor agonist transfer into breast milk or effects on nursing infants. Until more data exist, most guidance advises against using these medications during lactation.

How do GLP-1 receptor agonists compare to metformin for PCOS?

A 2025 network meta-analysis in Frontiers in Endocrinology (PMID 42490840) found GLP-1 receptor agonists produced greater reductions in BMI, fasting insulin, and testosterone compared with metformin and inositol in women with PCOS. Metformin still has a much longer safety record in this population, including during early pregnancy.

What did the tirzepatide plus metformin trial find for women with PCOS?

A 12-week prospective randomized trial in overweight and obese Chinese women with PCOS (PMID 42236268) found that adding tirzepatide to metformin produced greater improvements in BMI, fasting glucose, testosterone, and menstrual regularity than metformin alone. The trial was short-term and did not assess pregnancy outcomes.

Are more women with PCOS being prescribed GLP-1 medications now?

Yes. A real-world cohort study from a Polish private healthcare network (PMID 42297761) documented a sharp rise in incretin prescriptions for women with PCOS between 2019 and 2023, with semaglutide becoming the dominant agent by the end of that period. The authors noted this prescribing growth has outpaced reproductive safety evidence.

Should women with PCOS who become pregnant while on a GLP-1 stop immediately?

An unplanned pregnancy while on a GLP-1 medication warrants an immediate conversation with a healthcare provider—do not make that decision alone. The 2025 systematic review (PMID 41885132) found no evidence that brief early-pregnancy exposure causes a specific harm, but it also found no evidence of safety, making prompt medical guidance essential.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.